Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability

详细信息    查看全文

• 作者：Songhua Xiao^a ; ¹ ; Daoyou Zhou^b ; ¹ ; Ping Luan^c ; Beibei Gu^d ; Longbao Feng^e ; Shengnuo Fan^a ; Wang Liao^a ; Wenli Fang^a ; Lianhong Yang^a ; Enxiang Tao^a ; Rui Guo^e ; ^{guorui@jnu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Jun Liu^a ; ^f ; ^g ; ^{docliujun@hotmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Graphene quantum dots ; Neuroprotective peptide ; Amyloid-β (Aβ) ; Dendritic spine ; Alzheimer disease (AD)
• 刊名：Biomaterials
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：106
• 期：Complete
• 页码：98-110
• 全文大小：5394 K

文摘

Alzheimer disease (AD) is a neurodegenerative disorder and the most common form of dementia. Histopathologically is characterized by the presence extracellular neuritic plaques and with a large number of neurons lost. In this paper, we design a new nanomaterial, graphene quantum dots (GQDs) conjugated neuroprotective peptide glycine-proline-glutamate (GQDG) and administer it to APP/PS1 transgenic mice. The in vitro assays including ThT and CD proved that GQDs and GQDG could inhibit the aggregation of Aβ_1-42 fibrils. Morris water maze was performed to exanimate learning and memory capacity of APP/PS1 transgenic mice. The surface area of Aβ plaque deposits reduced in the GQDG group compared to the Tg Ctrl groups. Furthermore, newly generated neuronal precursor cell and neuron were test by immunohistochemical. Besides, neurons were impregnated by DiI using gene gun to show dendritic spine. Results indicated enhancement of learning and memory capacity and increased amounts of dendritic spine were observed. Inflammation factors and amyloid-β (Aβ) were tested with suspension array and ELISA, respectively. Several pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-33, IL-17α, MIP-1β and TNF-α) had decreased in GQDG group compared with Control group. Reversely, anti-inflammatory cytokines (IL-4, IL-10) had increased in GQDG group compared with Control group. Thus, we demonstrate that the GQDG is a promising drug in treatment of neurodegenerative diseases such as AD.